Literature DB >> 19417153

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Changye Y Zou1, Kerrington D Smith, Quan-Sheng Zhu, Jun Liu, Ian E McCutcheon, John M Slopis, Funda Meric-Bernstam, Zhenghong Peng, William G Bornmann, Gordon B Mills, Alexander J Lazar, Raphael E Pollock, Dina Lev.   

Abstract

The mammalian target of rapamycin (mTOR) pathway may constitute a potential target for the treatment of malignant peripheral nerve sheath tumors (MPNST). However, investigations of other cancers suggest that mTOR blockade can paradoxically induce activation of prosurvival, protumorigenic signaling molecules, especially upstream AKT. Consequently, we hypothesized that dual phosphatidylinositol 3-kinase (PI3K)/AKT-mTOR blockade might be applicable for MPNST treatment. Expression of activated mTOR downstream targets (p4EBP1 and pS6RP) and pAKT was evaluated immunohistochemically in a tissue microarray of human MPNSTs (n = 96) and benign neurofibromas (n = 31). Results were analyzed by Wilcoxon rank-sum tests. mTOR and AKT pathways in human MPNST cell lines, and the effects of rapamycin (mTOR inhibitor), LY294002 (dual PI3K/mTOR inhibitor), and PI-103 (potent dual PI3K/AKT-mTOR inhibitor) on pathway activation were evaluated by Western blot. Effects on cell growth were evaluated via MTS and colony formation assays. Cell cycle progression and apoptosis were assessed by propidium iodide/fluorescence-activated cell sorting staining and Annexin V assays. Acridine orange staining/fluorescence-activated cell sorting analysis, electron microscopy, and Western blot evaluated autophagy induction. p4EBP1, pS6Rp, and pAKT levels were found to be significantly higher in MPNST versus neurofibroma (P < 0.05 for all markers). mTOR and AKT pathways were found to be highly activated in MPNST cell lines. MPNST cells were sensitive to rapamycin; however, rapamycin enhanced pAKT and peIF4E expression. PI-103 abrogated MPNST cell growth and induced G(1) cell cycle arrest potentially through repression of cyclin D1. PI-103 did not elicit apoptosis but significantly induced autophagy in MPNST cells. These results suggest further study of combined PI3K/AKT and mTOR inhibition as a novel therapy for patients harboring MPNST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417153     DOI: 10.1158/1535-7163.MCT-08-1008

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  40 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

2.  In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.

Authors:  Dexin Kong; Takao Yamori; Kanami Yamazaki; Shingo Dan
Journal:  Invest New Drugs       Date:  2014-08-26       Impact factor: 3.850

3.  PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Authors:  Roberto Gedaly; Paul Angulo; Jonathan Hundley; Michael F Daily; Changguo Chen; Alvaro Koch; B Mark Evers
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

Review 4.  Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.

Authors:  Lama Binobaid; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-27

5.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Wei Mo; Jian Chen; Amish Patel; Liang Zhang; Vincent Chau; Yanjiao Li; Woosung Cho; Kyun Lim; Jing Xu; Alexander J Lazar; Chad J Creighton; Svetlana Bolshakov; Renée M McKay; Dina Lev; Lu Q Le; Luis F Parada
Journal:  Cell       Date:  2013-02-21       Impact factor: 41.582

Review 6.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

7.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Authors:  Gautam Prasad; Theo Sottero; Xiaodong Yang; Sabine Mueller; C David James; William A Weiss; Mei-Yin Polley; Tomoko Ozawa; Mitchel S Berger; Dana T Aftab; Michael D Prados; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2011-02-11       Impact factor: 12.300

8.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

9.  Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Authors:  Markus P Ghadimi; Gonzalo Lopez; Keila E Torres; Roman Belousov; Eric D Young; Jeffery Liu; Kari J Brewer; Aviad Hoffman; Kristelle Lusby; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

10.  Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.

Authors:  Kelsey L Watson; Ghadah A Al Sannaa; Christine M Kivlin; Davis R Ingram; Sharon M Landers; Christina L Roland; Janice N Cormier; Kelly K Hunt; Barry W Feig; B Ashleigh Guadagnolo; Andrew J Bishop; Wei-Lien Wang; John M Slopis; Ian E McCutcheon; Alexandar J Lazar; Keila E Torres
Journal:  J Neurosurg       Date:  2016-04-01       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.